Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Conteduca, Vincenza ^a   Crabb, Simon J ^b   Jones, Robert J ^c   Caffo, Orazio ^d   Elliott, Tony ^e   Scarpi, Emanuela ^a   Fabbri, Paolo ^f   Derosa, Lisa ^g   Massari, Francesco ^h   Numico, Gianmauro ⁱ   Zarif, Sunnya ^b   Hanna, Catherine ^c   Maines, Francesca ^d   Joyce, Helen ^e   Lolli, Cristian ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SANTA CHIARA HOSPITAL   (Italy)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f Cervesi Hospital   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ Aosta Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; DISEASE FREE SURVIVAL; DRUG EFFECTS; KAPLAN MEIER METHOD; LYMPHOCYTE; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 84979516598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158952     Document Type: Article

References (36)

1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154. doi: 10.1016/S0140-6736(10)61389-X PMID: 20888992
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005. doi: 10.1056/NEJMoa1014618 PMID: 21612468
3. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368: 138-148. doi: 10.1056/NEJMoa1209096 PMID: 23228172
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-1197. PMID: 22894553
5. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371: 424-433. doi: 10.1056/NEJMoa1405095 PMID: 24881730
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422. doi: 10.1056/NEJMoa1001294 PMID: 20818862
7. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369: 213-223. doi: 10.1056/NEJMoa1213755 PMID: 23863050
8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-867. PMID: 12490959
9. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436-444. doi: 10.1038/nature07205 PMID: 18650914
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
11. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to- lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106: 1-11.
12. Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2013; 114: E11-E17.
13. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012; 17: 1508-1514. doi: 10.1634/theoncologist.2012-0125 PMID: 22971522
14. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, et al. Prognostic impact of the neutrophil-to- lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014; 12: 317-324. doi: 10.1016/j.clgc.2014.03.005 PMID: 24806399
15. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26: 750-755. doi: 10.1093/annonc/mdu587 PMID: 25538172
16. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration- resistant prostate cancer. Ann Oncol. 2014; 25: 657-662. doi: 10.1093/annonc/mdt581 PMID: 24458472
17. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375: 1437-1446. doi: 10.1016/S0140-6736(10)60172-9 PMID: 20398925
18. Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and B lymphocytes to the bone marrow. Immunology. 1975; 28: 669-680. PMID: 1080130
19. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med. 2005; 353: 1711-1723. PMID: 16236742
20. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159. doi: 10.1200/JCO.2007.12.4487 PMID: 18309951
21. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65: 467-479. doi: 10.1016/j.eururo.2013.11.002 PMID: 24321502
22. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7: 256-269. PMID: 17384581
23. Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumour-infiltrating Gr-1(+) myeloid cells antagonize senescence in cancer. Nature. 2014; 515: 134-137. doi: 10.1038/nature13638 PMID: 25156255
24. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009; 348: 9-17. doi: 10.1016/j.jim.2009.06.004 PMID: 19552894
25. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear factor kappa B target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappa B inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006; 12: 5578-5586. PMID: 17000695
26. Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, et al. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015; 112: 1340-1348. doi: 10.1038/bjc.2015.74 PMID: 25867259
27. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 2009; 69: 7696-7703. doi: 10.1158/0008-5472.CAN-08-4901 PMID: 19773444
28. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther. 2008; 327: 746-759. doi: 10.1124/jpet.108.143826 PMID: 18780829
29. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012; 13: 1114-1124. doi: 10.1016/S1470-2045(12)70372-8 PMID: 23059046
30. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012; 13: 1105-1113. doi: 10.1016/S1470-2045(12)70263-2 PMID: 23059047
31. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008; 112: 2377-2383. doi: 10.1002/cncr.23461 PMID: 18428198
32. Alicia C. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, et al. Association Between Systemic Inflammatory Markers and Serum Prostate-Specific Antigen in Men without Prostatic Disease - The 2001-2008 National Health and Nutrition Examination Survey. Prostate. 2014; 74: 561-567. doi: 10.1002/pros.22782 PMID: 24435840
33. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009; 124: 2683-2689. doi: 10.1002/ijc.24241 PMID: 19189403
34. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: Evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 2012; 15: 195-201. doi: 10.1038/pcan.2011.60 PMID: 22343838
35. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Follow up of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012; 187: 411-417. doi: 10.1016/j.juro.2011.10.026 PMID: 22177153
36. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015; 22: 1377-1384. doi: 10.1245/s10434-014-4097-4 PMID: 25234022